Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
ES08 - Sublobar Resection: Oncological Outcome and Advantages
- 14:30 - 15:30
- 8/07/2022
- Location: Hall C1
- IASLC CME Accredited
- Type: Education Session
- Track: Early Stage Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments - Surgery
- Moderators:Masahiro Tsuboi, Monica Casiraghi
-
+
ES08.05 - Are There Benefits of Sublobar Resection Including Lung Function
14:56 - 15:08 | Presenter: Nasser Khaled Altorki
- Abstract
Loading...
-
+
EP02.04 - Early Stage Non-small Cell Lung Cancer - Systemic Therapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Early Stage Non-small Cell Lung Cancer - Systemic Therapy
-
+
EP02.04-004 - Time to Surgery After Neoadjuvant Immunotherapy: Not a Day Too Soon
Presenter: Nathan Mynard- Abstract
Loading...
-
+
PL03 - Plenary 3: Presidential Symposium - Top Rated Abstracts (Live Streamed Session)
- 08:30 - 10:20
- 8/08/2022
- Location: Hall C1
- IASLC CME Accredited
- Type: Plenary
- Track: N/A
- Moderators:Heather Wakelee, Eric Lim
-
+
PL03.06 - Lobar or Sub-lobar Resection for Peripheral Clinical Stage IA = 2 cm Non-small Cell Lung Cancer (NSCLC): Results From an International Randomized Phase III Trial (CALGB 140503 [Alliance])
Presenter: Nasser Khaled Altorki- Abstract
Loading... -
+
PL03.09 - IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC
Presenter: ENRIQUETA FELIP- Abstract
Loading...
-
+
OA09 - Precision Immunotherapy via Modulation of the Tumor Microenvironment
- 14:45 - 15:45
- 8/08/2022
- Location: Lehar 1
- Not for CME Credit
- Type: Oral
- Track: Tumor Biology and Biomarkers
- Moderators:Kurt Alex Schalper, Umberto Malapelle
-
+
OA09.05 - Neoadjuvant IL-15-PDL1 Antibody Promotes T cell Memory and Decreases Metastatic Recurrence in Resectable NSCLC
15:07 - 15:17 | Presenter: Jonathan Villena-Vargas
- Abstract
Loading...